StockUS listing USBDTXNASDAQHealthcareQuality Compounder

Black Diamond Therapeutics Inc(BDTX) Stock Analysis | Healthcare

USD --+0.00%
Reward64Moderate
Risk72High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 75.28M
Reward Ratingⓘ64 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BDTX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Black Diamond Therapeutics Inc?

, a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.

AI Brief Pro

The brief on Black Diamond Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Black Diamond Therapeutics Inc?

, a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 75.28M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (64)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta3.455
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.